Cite
APA Citation
Hilley, P., Wong, D., Ma, R., Peterson, A., & De Cruz, P. (n.d.). p028 Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease – what is the opportunity cost of improving access to health care?. Journal of Crohn's and colitis, 17, i197–i198. http://access.bl.uk/ark:/81055/vdc_100179844252.0x000031